Allopregnanolone (Zuranolone) in Post-stroke Depression
Start Date
1/14/2026
Completion Date
6/30/2026
Summary
The goal of this Phase II clinical trial is to learn if the oral synthetic allopreganolone analog (zuranolone) is safe to take and is well tolerated by stroke survivors experiencing moderate to severe post-stroke depression and if it will help with the symptoms of depression. The main questions it will aim to answer are: * Is zuranolone safe to take by participants who have moderate to severe post-stroke depression? * Is zuranolone well-tolerated by participants who have moderate to severe post-stroke depression? * Does zuranolone treat moderate to severe post-stroke depression? The study will enroll six participants. All participants will be given 50 mg of zuranolone for 14 days. Participants will be asked to provide blood samples, complete some questionnaires including those related to mood and a cognitive assessment.
Eligibility Criteria
Age Range: 21 years to 65 years
Interventions
Zuranolone
Conditions
Locations
Duke South Neurology Clinic 1L
Durham, North Carolina 27710-0400
United States